Ischemia modified albumin and plasma oxidative stress markers in Alzheimer's disease

European Neurology

Volumn 69, Issue 6, 2013, Pages 377-380

  Can, Murat ^a,c   Varlibas, Figen ^b   Guven, Berrak ^a   Akhan, Ozkan ^b   Yuksel, Gulbun Asuman ^b  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^b Research Hospital   (Turkey)

^c University of Medicine   (Turkey)

Author keywords

Albumin; Alzheimer's disease; Gamma glutamyltransferase; Ischemia modified albumin; Uric acid

Indexed keywords

ALBUMIN; GAMMA GLUTAMYLTRANSFERASE; ISCHEMIA MODIFIED ALBUMIN; URIC ACID; BIOLOGICAL MARKER;

AGED; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECTROPHOTOMETRY; URIC ACID BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; OXIDATIVE STRESS; SERUM ALBUMIN; URIC ACID;

EID: 84878706647     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000339006     Document Type: Article

References (32)

1. Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA: Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol 2006; 111: 503-509. (Pubitemid 43778954)
2. Butterfield DA, Lauderback CM: Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002; 32: 1050-1060. (Pubitemid 34603342)
3. Bush AI, Curtain CC: Twenty years of metallo-neurobiology: where to now? Eur Biophys J Biophys Lett 2008; 37: 241-245.
4. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E: The antioxidant properties of serum albumin. FEBS Lett 2008; 582: 1783-1787.
5. Bourdon E, Blache D: The importance of proteins in defense against oxidation. Antioxid Redox Sign 2001; 3: 293-311. (Pubitemid 32473344)
6. Waugh WH: Inhibition of iron-catalyzed oxidations by attainable uric acid and ascorbic acid levels: therapeutic implications for Alzheimer's disease and late cognitive impairment. Gerontology 2008; 54: 238-243. (Pubitemid 351862051)
7. Whitfield JB: Gamma-glutamyl transferase. Crit Rev Clin Lab Sci 2001; 38: 263-355.
8. Lee DH, Blomhoff R Jr, Jacobs DR: Is serum gamma-glutamyltransferase a marker of oxidative stress? Free Radic Res 2004; 38: 535-539.
9. Lee DH, Jacobs DR, Gross M, Kiefe CI, Roseman J, Lewis CE, Steffes M: Gamma-glutamyltransferase is predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003; 49: 1358-1366. (Pubitemid 36900623)
10. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E: Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001; 268: 42-47. (Pubitemid 32054374)
11. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
13. Folstein MF, Folstein JE, McHugh PR: 'Minimental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
14. Stahelin HB, Monsch AU, Spiegel R: Early diagnosis of dementia via a two-step screening and diagnostic procedure. Int Psychogeriatr 1997; 9: 123-130. (Pubitemid 28045349)
15. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale scale for the staging of dementia. Brit J Psychiat 1982; 140: 566-572. (Pubitemid 12124384)
16. Bar-Or D, Lau E, Winkler JV: A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000; 19: 311-315.
17. Leutner S, Schindowski K, Frolich L, Maurer K, Kratzsch T, Eckert A, Muller WE: Enhanced ROS-generation in lymphocytes from Alzheimer's patients. Pharmacopsychiatry 2005; 38: 312-315. (Pubitemid 41815688)
18. Axelsen PH, Komatsu H, Murray IV: Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. Physiology 2011; 26: 54-69.
19. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P: Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003; 24: 915-919. (Pubitemid 36962976)
20. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU: Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psych 2006; 21: 344-348.
21. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, Richard-Harston S, Decamps A, Reignier B, Emeriau JP, Rainfray M: Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001; 30: 235-241. (Pubitemid 32684904)
22. Yavuz BB, Yavuz B, Halil M, Cankurtaran M, Ulger Z, Cankurtaran ES, Aytemir K, Ariogul S: Serum elevated gamma-glutamyltransferase levels may be a marker for oxidative stress in Alzheimer's disease. Int Psychogeriatr 2008; 20: 815-823. (Pubitemid 351704878)
23. Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, Honda SA, Rios CN, Sugiyama CE, Ha CE: Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003; 49: 581-585. (Pubitemid 36379523)
24. Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, Januzzi JL, Jesse RL, Kaski JC, Kontos MC, Lefevre G, Mutrie D, Sinha MK, Uettwiller-Geiger D, Pollack CV: Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 2006; 152: 253-262. (Pubitemid 44093396)
25. Kaefer M, Piva SJ, De Carvalho JA, Da Silva DB, Becker AM, Coelho AC, Duarte MM, Moresco RN: Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010; 43: 450-454.
26. Valle Gottlieb MG, da Cruz IB, Duarte MM, Moresco RN, Wiehe M, Schwanke CH, Bodanese LC: Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocr Metab 2010; 95: 586-591.
27. Kotani K, Kimura S, Gugliucci A: Paraoxonase-and ischemia-modified albumin in patients with end-stage renal disease. J Physiol Biochem 2011; 67: 437-441.
28. Caglar GS, Oztas E, Karadag D, Pabuccu R, Demirtas S: Ischemia-modified albumin and cardiovascular risk markers in polycystic ovary syndrome with or without insulin resistance. Fertil Steril 2011; 95: 310-313.
29. Can M, Demirtas S, Polat O, Yildiz A: Evaluation of effects of ischaemia on the albumin cobalt binding (ACB) assay in patients exposed to trauma. Emerg Med J 2006; 23: 537-539. (Pubitemid 44295259)
30. Ahn JH, Choi SC, Lee WG, Jung YS: The usefulness of albumin-adjusted ischemia-modified albumin index as early detecting marker for ischemic stroke. Neurol Sci 2011; 32: 133-138.
31. Gunduz A, Turedi S, Mentese A, Altunayoglu V, Turan I, Karahan SC, Topbas M, Aydin M, Eraydin I, Akcan B: Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med 2008; 26: 874-878.
32. Abboud H, Labreuche J, Meseguer E, Lavallee PC, Simon O, Olivot JM, Mazighi M, Dehoux M, Benessiano J, Steg PG, Amarenco P: Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007; 23: 216-220. (Pubitemid 46239165)